Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.
| Revenue (TTM) | $13.60B |
| Gross Profit (TTM) | $4.26B |
| EBITDA | $1.08B |
| Operating Margin | 5.76% |
| Return on Equity | 8.85% |
| Return on Assets | 4.39% |
| Revenue/Share (TTM) | $116.77 |
| Book Value | $28.21 |
| Price-to-Book | 3.09 |
| Price-to-Sales (TTM) | 0.71 |
| EV/Revenue | 0.985 |
| EV/EBITDA | 13.27 |
| Quarterly Earnings Growth (YoY) | 17.10% |
| Quarterly Revenue Growth (YoY) | 6.70% |
| Shares Outstanding | $111.45M |
| Float | $91.71M |
| % Insiders | 0.83% |
| % Institutions | 112.19% |
Volatility is currently contracting
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Cares, Henry Schein, Inc.'s global corporate citizenship program, is celebrating a quarter century of bringing together Team Schein Members, customers, supplier partners, healthcare professionals, nonprofit organizations, and communities to help make the world healthier. Today, Henry Schein Cares reflects the Company's broader approach to corporate citizenship through five interconnected pillars: Catalyzing Healthcare Access; Advancing Policies, Sol.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein is rated buy with a 12-month price target of $104, reflecting accelerating organic growth, margin expansion, and substantial share repurchases. Q2 2026 results showed 4.6% internal growth, 48 bps gross margin expansion, and a 6.7% reduction in diluted share count, signaling improved business quality. The BOLD+1 cost program targets $125M+ in annual run-rate operating income gains by end-2026, supporting double-digit earnings growth potential into 2027.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HSIC and any ticker you trade — then tracks every position and per-strategy win rate.
